– An analgesic effect demonstrated –
– No increase in body temperature nor change in heat pain perception –
Montreal, October 30, 2017 – The NEOMED Institute announced today that it will present a poster on the Phase II data for its lead program NEO6860 during the American College of Rheumatology’s Annual Meeting, the world’s premier rheumatology meeting.
The poster titled “Analgesic Potential of NEO6860, a Modality Selective TRPV1 Antagonist, in Osteoarthritis Knee Pain: Results of a Randomized, Controlled, Proof-of-Concept Trial” will be available for viewing for the duration of the meeting that will be held in San Diego, CA,USA, November 3-8, 2017 and will be posted on NEOMED’s website thereafter.
“We are excited by the outcome of this study,” said Dr Richard Leff who will present the data on behalf of NEOMED, “not only do we believe that we have likely demonstrated NEO6860 to have an analgesic effect in a controlled setting, but we have clearly shown that NEO6860 does not have the most concerning side effects that have led to other TRPV1 programs to have been discontinued in the past.”
“This is an important achievement,” adds Dr. Nathaniel Katz, CEO at Analgesic Solutions. “In the past decades, very few new molecules with new mechanisms of action have reached this point. NEO6860 may become the first effective and safe TRPV1 program to successfully reach the market and provide a much needed alternative to patients who continue to suffer from pain associated with osteoarthritis.”
NEO6860, a new drug, under investigation for the treatment of osteoarthritic (OA) pain, shows potent antagonism of human TRPV1 when capsaicin is used as a stimulus in vitro, and has little or no effect against activation by low pH or heat. This profile, described as modality-selective TRPV1 antagonism, is predicted to relieve OA pain without the effects on body temperature or heat-pain threshold reported in the clinic with previous modality-nonselective TRPV1 antagonists.
Osteoarthritis (OA) is a musculoskeletal disorder involving degradation of joints, regularly associated with pain, which is the most debilitating symptom. OA of the knee is very common with approximately 250 million people with the condition globally. While pharmacotherapy is the cornerstone for the medical management of patients OA, there are significant limitations, in terms of efficacy as well as safety. Clinical effects of current drugs are small and limited to the first few weeks after start of treatment. In addition, there are significant risks associated with the use of current therapy, especially cardiovascular and gastrointestinal risks. A potent compound acting through a different mechanism, on a new target, would be desirable to circumvent the pitfalls of existing therapies.
About NEOMED Institute
NEOMED Institute is a not‐for‐profit organization whose mission is to bridge the gap between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with the creation of a vibrant and sustainable life science ecosystem. NEOMED operates two fully integrated research and development campuses in Montreal: one specializing in small molecule therapeutics, and the other specializing in the development of biologics and vaccines. Both facilities function as open‐access drug discovery hubs housing independent commercial businesses (30 independent companies employing more than 300 people) and providing a dynamic environment that stimulates collaboration, innovation, and creativity. NEOMED’s wholly-owned for-profit subsidiary, NEOMED-LABS, a Contract Research Organization (CRO) providing customized and high-throughput immune-monitoring for clinical vaccine development, is one of these tenants.
NEOMED is jointly funded by our pharmaceutical partners, the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada. For more information, please visit our website: www.neomed.ca
For more information, please contact:
President & CEO
Montreal, Quebec,Canada H4S 1Z9
514-367-1212 Ext. 206